A CDMO, or contract development and manufacturing organization, is a company that pharmaceutical and biotech firms hire to both develop and manufacture their drugs. Unlike a simple contract manufacturer that only produces a finished product, a CDMO handles the scientific development work needed to turn a drug candidate into a reliably manufacturable product, then scales production from small clinical batches all the way to full commercial supply. The global CDMO market was valued at roughly $234 billion in 2024 and is projected to reach $407 billion by 2032, reflecting how central outsourcing has become to the pharmaceutical industry.
How a CDMO Differs From a CMO or CRO
Three acronyms come up frequently in pharma outsourcing, and they describe distinct roles. A CMO (contract manufacturing organization) offers manufacturing services for clinical and commercial products but generally works from a process that’s already been developed. You hand them a recipe, and they produce the drug. A CRO (contract research organization) handles research tasks like running clinical trials, managing regulatory submissions, or performing lab testing, but doesn’t manufacture anything.
A CDMO sits between these two. It combines the development expertise of a CRO with the production capabilities of a CMO. That means a CDMO can take an early-stage molecule, figure out the best way to formulate and produce it, optimize that process for large-scale manufacturing, and then run the production lines. This end-to-end scope is the core value proposition: a drug company can work with a single partner from the lab bench through commercial launch rather than coordinating handoffs between multiple vendors.
What Services CDMOs Provide
CDMOs cover a wide arc of the drug lifecycle. On the development side, their work typically begins with route scouting and lab feasibility, where scientists evaluate different chemical or biological pathways to produce a drug compound and determine which approach is most practical. From there, the process moves through several defined stages:
- Process optimization: Refining reaction conditions, yields, and purification steps to make production consistent and cost-effective.
- Pilot-scale demonstration: Running the process at an intermediate scale to identify problems that don’t appear in small lab batches.
- Engineering and scale-up batches: Producing larger quantities to confirm the process works in full-sized equipment.
- GMP qualification batches: Manufacturing under strict regulatory conditions to generate data for submissions to agencies like the FDA. These batches support the formal validation and filing needed before a drug can reach patients.
Beyond the core chemistry and manufacturing work, many CDMOs offer analytical method development, formulation services (deciding whether a drug should be a tablet, injectable, capsule, or other form), stability testing, and packaging. Some also assist with regulatory strategy, helping clients compile the manufacturing data that regulatory agencies require.
Specialized Manufacturing Capabilities
The CDMO industry has expanded well beyond traditional small-molecule pills. As the pharmaceutical pipeline has shifted toward complex biologics and advanced therapies, CDMOs have built specialized capabilities to match. Major areas include:
Monoclonal antibodies and other therapeutic proteins, which require mammalian or microbial cell culture systems and sophisticated purification. Viral vectors for gene therapy, including adeno-associated virus (AAV) platforms that support programs from preclinical stages through commercial production. Cell therapies, which involve manufacturing living cells as the drug product itself. Messenger RNA production, which gained visibility during COVID-19 vaccine development and now supports a broader pipeline of RNA-based drugs. Plasmid DNA manufacturing, which serves as a starting material for gene therapies, viral vectors, and mRNA products.
These advanced modalities require highly specialized facilities and expertise that most drug developers, especially smaller biotech companies, cannot justify building in-house. A startup developing a gene therapy, for example, would need hundreds of millions of dollars and years of construction to build its own viral vector manufacturing plant. Partnering with a CDMO that already has that infrastructure lets the company stay lean and move faster.
Why Drug Companies Use CDMOs
The primary reasons are speed, cost, and risk reduction. Building and qualifying a manufacturing facility takes years and enormous capital investment. For a biotech company with a single drug candidate still in clinical trials, that investment makes little sense when the drug might never reach approval. A CDMO lets the company access production capacity without the fixed overhead.
Scale-up is also a technically risky phase of drug development. Chemical processes that work perfectly at a 1-liter scale can behave unpredictably at 1,000 liters. CDMOs with decades of experience navigating these transitions reduce the likelihood of costly failures. According to NIH guidance for drug innovators, using a CDMO for scale-up support specifically reduces risk and shortens lead times compared to attempting it independently.
Even large pharmaceutical companies with their own manufacturing networks use CDMOs. They may need additional capacity for a product launch, require a technology platform they don’t have in-house, or want to keep internal resources focused on their highest-priority programs. Outsourcing allows these companies to stay agile while still accessing differentiated drug development support.
Regulatory Standards CDMOs Must Meet
Any facility manufacturing drugs for human use must comply with current good manufacturing practice (cGMP) regulations. In the United States, the FDA enforces these standards under federal regulations that set minimum requirements for manufacturing methods, facilities, and quality controls. CDMOs are held to the same standards as any in-house pharmaceutical manufacturer, and FDA inspectors audit their facilities regularly.
For CDMOs operating globally, compliance extends to equivalent standards from agencies like the European Medicines Agency and other national regulators. A robust quality management system is non-negotiable: this includes documented procedures, deviation tracking, change control, and thorough record-keeping. When pharmaceutical companies evaluate potential CDMO partners, compliance history and regulatory reputation are among the first things they assess, alongside technical competence and project management track record.
How Companies Choose a CDMO
Selecting the right CDMO is one of the most consequential decisions a drug developer makes, because switching partners mid-program can cause costly delays. NIH guidance for innovators highlights several key evaluation criteria. Technical competence comes first: does the CDMO have proven experience with the specific technology platform, molecule type, and dosage form your product requires? A CDMO with deep expertise in small-molecule chemistry may not be the right fit for a cell therapy program.
Quality and compliance history matter enormously. A CDMO with a pattern of FDA warning letters or failed inspections represents a direct risk to your product’s timeline and approval. Beyond technical and quality factors, practical considerations like having a dedicated project manager, a track record of meeting timelines and budgets, and clear communication processes can make the difference between a smooth partnership and a frustrating one. Many companies also weigh geographic location, intellectual property protections, and whether the CDMO can support their product from early development all the way through commercial supply, avoiding the disruption of transferring to a new manufacturer later.
Major CDMOs in the Industry
The CDMO landscape includes hundreds of companies ranging from niche specialists to global giants. The largest by 2024 revenue was Lonza Group, a Swiss company generating $8.14 billion. Thermo Fisher Scientific followed at $7 billion, with Catalent at $4.43 billion. Samsung Biologics ($3.28 billion) and WuXi Biologics ($2.59 billion) round out the top five, reflecting the industry’s global footprint across Europe, North America, and Asia.
Other significant players include Siegfried, Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim’s contract manufacturing division, Recipharm, and MilliporeSigma. The industry’s projected growth rate of about 7.25% annually through 2032 continues to attract new entrants and investment, driven by an expanding pipeline of complex biologics and the ongoing trend of pharmaceutical companies choosing to outsource rather than build.